{"schema_version":"1.0","type":"article","title":"1,432 人三期未達標：Eplontersen 加上標準治療後還剩多少價值？","url":"https://drugnews.com.tw/articles/2026-09-13-eplontersen-attr-cm-incremental-value.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-13-eplontersen-attr-cm-incremental-value.md","lang":"zh-Hant","date":"2026-09-13","publish_at":"2026-09-13T08:00:00+08:00","updated_at":"2026-09-13","category":"商業分析系列","topic":"商業分析系列","tags":["ATTR-CM","eplontersen","CARDIO-TTRansform","RNA silencing","stabilizer","增量價值"],"summary":"CARDIO-TTRansform 整體主要終點未達標後，eplontersen 的價值必須回到背景 stabilizer、時間分層與真正可驗證的加成效果。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"圖 1｜1,432 人三期未達標","url":"https://drugnews.com.tw/assets/articles/eplontersen-attr-cm-incremental-value/01_%E4%B8%80%E5%8D%83%E5%9B%9B%E7%99%BE%E4%B8%89%E5%8D%81%E4%BA%8C%E4%BA%BA%E4%B8%89%E6%9C%9F%E6%9C%AA%E9%81%94%E6%A8%99_typed_v1.png"},{"alt":"圖 2｜ATTR 的兩個介入點不保證結果相加","url":"https://drugnews.com.tw/assets/articles/eplontersen-attr-cm-incremental-value/02_TTR%E5%85%A9%E5%80%8B%E4%BB%8B%E5%85%A5%E9%BB%9E_typed_v1.png"},{"alt":"圖 3｜57% baseline 與另 24% on-study 不是同一時間點","url":"https://drugnews.com.tw/assets/articles/eplontersen-attr-cm-incremental-value/03_%E8%83%8C%E6%99%AF%E6%B2%BB%E7%99%82%E6%99%82%E9%96%93%E5%88%86%E5%B1%A4_typed_v1.png"},{"alt":"圖 4｜下一題是誰先用、誰加藥、值不值得付","url":"https://drugnews.com.tw/assets/articles/eplontersen-attr-cm-incremental-value/04_%E5%A2%9E%E9%87%8F%E5%83%B9%E5%80%BC%E8%88%87%E5%8F%B0%E7%81%A3%E4%BA%9E%E6%B4%B2%E6%B1%BA%E7%AD%96_typed_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/eplontersen-attr-cm-incremental-value/01_%E4%B8%80%E5%8D%83%E5%9B%9B%E7%99%BE%E4%B8%89%E5%8D%81%E4%BA%8C%E4%BA%BA%E4%B8%89%E6%9C%9F%E6%9C%AA%E9%81%94%E6%A8%99_typed_v1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-13）。1,432 人三期未達標：Eplontersen 加上標準治療後還剩多少價值？。https://drugnews.com.tw/articles/2026-09-13-eplontersen-attr-cm-incremental-value.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}